PLA2R-THSD7A fusion protein as well as application and kit thereof

A technology of fusion protein and diagnostic kit, applied in the field of PLA2R-THSD7A fusion protein and its application and kit, to achieve good specificity, simple method, and improved sensitivity
CN106432508AActive Publication Date: 2017-02-22SHENZHEN BLOT BIOTECH
8 Cites 7 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHENZHEN BLOT BIOTECH
Publication Date
2017-02-22

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the medical field and particularly relates to a PLA2R-THSD7A fusion protein as well as application and kit thereof. The fusion protein comprises a first region and a second region, wherein the first region has at least 85% of sequence homology with a phospholipase A2 receptor (PLA2R), and the second region has at least 85% of sequence homology with 1-type thrombospondin 7A domain (THSD7A). The fusion protein prepared by virtue of the preparation method integrates epitopes of two antibodies including PLA2R and THSD7A and simultaneously has the immunoreactivities of the two antibodies, and the detection ratio of spontaneity MN-relevant autoantibodies is increased and can reach 78.1%.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of medicine, in particular to a PLA2R-THSD7A fusion protein and its application and kit. Background technique

[0002] Primary membranous glomerulonephritis (pMGN), also known as idiopathic membranous nephropathy (IMN), is a chronic glomerular inflammatory disease and one of the common types of nephropathy in nephrotic syndrome. The typical feature of the disease is proteinuria, with the increase of urinary protein content, there is a tendency to develop renal failure. Most pMGN patients present with nephrotic syndrome, some with edema, weight gain, and decreased urination. pMGN differs from secondary membranous glomerulonephritis (sMGN), which is a secondary or concurrent disease. Drug treatment, substance abuse, infectious diseases, other autoimmune diseases, and tumors may all lead to the occurrence of sMGN. At the same time, sMGN can improve with the treatment of the underlying disease. The "gold standard" for...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More